[go: up one dir, main page]

MA33824B1 - Agonistes du recepteur mglu2 - Google Patents

Agonistes du recepteur mglu2

Info

Publication number
MA33824B1
MA33824B1 MA34967A MA34967A MA33824B1 MA 33824 B1 MA33824 B1 MA 33824B1 MA 34967 A MA34967 A MA 34967A MA 34967 A MA34967 A MA 34967A MA 33824 B1 MA33824 B1 MA 33824B1
Authority
MA
Morocco
Prior art keywords
receptor agonists
mglu2 receptor
agonists
mglu2
schizophrenia
Prior art date
Application number
MA34967A
Other languages
Arabic (ar)
English (en)
Inventor
James Allen Monn
Lourdes Prieto
Martinez Lorena Taboada
Salgado Carlos Montero
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33824(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33824B1 publication Critical patent/MA33824B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet de nouveaux agonistes de mglu2 utiles dans le traitement des troubles bipolaires, de la schizophrénie, de la dépression, et du trouble anxieux généralisé. Les nouveaux agonistes sont représentés par la formule.
MA34967A 2009-12-21 2012-06-14 Agonistes du recepteur mglu2 MA33824B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (fr) 2009-12-21 2010-12-15 Agonistes de mglu2

Publications (1)

Publication Number Publication Date
MA33824B1 true MA33824B1 (fr) 2012-12-03

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34967A MA33824B1 (fr) 2009-12-21 2012-06-14 Agonistes du recepteur mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (fr)
EP (1) EP2516406B1 (fr)
JP (1) JP5779190B2 (fr)
KR (1) KR101395356B1 (fr)
CN (1) CN102695701B (fr)
AR (1) AR079343A1 (fr)
AU (1) AU2010340039B2 (fr)
BR (1) BR112012017188B1 (fr)
CA (1) CA2784667C (fr)
CR (1) CR20120322A (fr)
CY (1) CY1114880T1 (fr)
DK (1) DK2516406T3 (fr)
DO (1) DOP2012000173A (fr)
EA (1) EA020229B1 (fr)
EC (1) ECSP12011989A (fr)
ES (1) ES2435651T3 (fr)
HN (1) HN2012001160A (fr)
HR (1) HRP20131052T1 (fr)
IL (1) IL220011A (fr)
JO (1) JO2978B1 (fr)
MA (1) MA33824B1 (fr)
MX (1) MX2012007332A (fr)
MY (1) MY160618A (fr)
NZ (1) NZ600305A (fr)
PE (1) PE20121688A1 (fr)
PH (1) PH12012501253A1 (fr)
PL (1) PL2516406T3 (fr)
PT (1) PT2516406E (fr)
RS (1) RS53063B (fr)
SG (1) SG181836A1 (fr)
SI (1) SI2516406T1 (fr)
TN (1) TN2012000281A1 (fr)
TW (1) TWI477490B (fr)
UA (1) UA107684C2 (fr)
WO (1) WO2011084437A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790284C (fr) 2010-02-17 2019-01-08 Takeda Pharmaceutical Company Limited Composes de thieno-pyrimidine presentant de l'activite inhibitrice de cdc7
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
SI2721012T1 (sl) * 2011-06-17 2016-08-31 Eli Lilly And Company Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kisline kot agonisti mglu2 receptorja
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EA033889B1 (ru) * 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
IL156364A0 (en) * 2001-01-11 2004-01-04 Lilly Co Eli Prodrugs of excitatory amino acids
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (fr) * 2001-02-22 2002-09-06 Eli Lilly And Company Acides amines excitateurs synthetiques
NZ564692A (en) * 2002-06-11 2009-05-31 Lilly Co Eli Prodrugs of excitatory amino acids
WO2005000790A1 (fr) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. Derive d'acide 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylique
US9056844B2 (en) * 2010-11-18 2015-06-16 Eli Lilly And Company 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3

Also Published As

Publication number Publication date
HK1171228A1 (en) 2013-03-22
EA020229B1 (ru) 2014-09-30
EP2516406A1 (fr) 2012-10-31
BR112012017188B1 (pt) 2021-06-22
HN2012001160A (es) 2015-08-24
ECSP12011989A (es) 2012-07-31
MY160618A (en) 2017-03-15
BR112012017188A8 (pt) 2016-10-04
TN2012000281A1 (en) 2013-12-12
SG181836A1 (en) 2012-08-30
DOP2012000173A (es) 2012-11-30
JP5779190B2 (ja) 2015-09-16
UA107684C2 (xx) 2015-02-10
ES2435651T3 (es) 2013-12-20
SI2516406T1 (sl) 2013-11-29
JO2978B1 (en) 2016-03-15
EA201290558A1 (ru) 2012-12-28
PH12012501253A1 (en) 2014-08-01
PL2516406T3 (pl) 2014-03-31
IL220011A0 (en) 2012-07-31
EP2516406B1 (fr) 2013-09-18
US20110152334A1 (en) 2011-06-23
CN102695701A (zh) 2012-09-26
JP2013514974A (ja) 2013-05-02
AU2010340039B2 (en) 2014-03-20
CY1114880T1 (el) 2016-12-14
BR112012017188A2 (pt) 2016-03-22
CA2784667A1 (fr) 2011-07-14
AR079343A1 (es) 2012-01-18
PE20121688A1 (es) 2012-12-05
AU2010340039A1 (en) 2012-08-09
CN102695701B (zh) 2014-10-01
TW201144290A (en) 2011-12-16
DK2516406T3 (da) 2013-10-14
CA2784667C (fr) 2014-11-18
MX2012007332A (es) 2012-07-20
US8318184B2 (en) 2012-11-27
TWI477490B (zh) 2015-03-21
NZ600305A (en) 2014-01-31
HRP20131052T1 (hr) 2013-12-06
CR20120322A (es) 2012-07-10
RS53063B (sr) 2014-04-30
PT2516406E (pt) 2013-10-10
KR20120094056A (ko) 2012-08-23
WO2011084437A1 (fr) 2011-07-14
KR101395356B1 (ko) 2014-05-14
IL220011A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MA33824B1 (fr) Agonistes du recepteur mglu2
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
EP2571360A4 (fr) Méthodes et formulations pour le traitement par l'oxytocine de troubles liés à l'utilisation de substances toxiques, de troubles psychiatriques et autres troubles
MA34839B1 (fr) Dihydrofuranes condensés en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles apparentes
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA37940B1 (fr) Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
SG178997A1 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
MA33428B1 (fr) Agonistes du gpr119
FR2981934B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EA201590854A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
IN2015DN03145A (fr)
TNSN07118A1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MA37990B1 (fr) Benzamides
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
IN2014CN03854A (fr)
EP2890370A4 (fr) Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.